Twist Bioscience Stock Forecast, Price & News

Twist Bioscience (NASDAQ:TWST) Frequently Asked Questions

Is Twist Bioscience a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Twist Bioscience stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TWST, but not buy additional shares or sell existing shares.
View analyst ratings for Twist Bioscience or view top-rated stocks.

How has Twist Bioscience's stock price been impacted by COVID-19 (Coronavirus)?

Twist Bioscience's stock was trading at $28.20 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TWST shares have increased by 187.7% and is now trading at $81.14.
View which stocks have been most impacted by COVID-19.

When is Twist Bioscience's next earnings date?

Twist Bioscience is scheduled to release its next quarterly earnings announcement on Thursday, February 3rd 2022.
View our earnings forecast for Twist Bioscience.

How were Twist Bioscience's earnings last quarter?

Twist Bioscience Co. (NASDAQ:TWST) issued its quarterly earnings data on Monday, November, 22nd. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.80) by $0.04. The firm earned $37.95 million during the quarter, compared to analysts' expectations of $36.26 million. Twist Bioscience had a negative net margin of 106.59% and a negative trailing twelve-month return on equity of 24.59%. The firm's revenue for the quarter was up 17.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.54) EPS.
View Twist Bioscience's earnings history.

What guidance has Twist Bioscience issued on next quarter's earnings?

Twist Bioscience issued an update on its first quarter 2022 earnings guidance on Monday, November, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $37 million-$39 million, compared to the consensus revenue estimate of $38.78 million.

What price target have analysts set for TWST?

5 equities research analysts have issued 12 month price objectives for Twist Bioscience's stock. Their forecasts range from $100.00 to $150.00. On average, they anticipate Twist Bioscience's stock price to reach $118.25 in the next year. This suggests a possible upside of 45.7% from the stock's current price.
View analysts' price targets for Twist Bioscience or view top-rated stocks among Wall Street analysts.

Who are Twist Bioscience's key executives?

Twist Bioscience's management team includes the following people:

• Emily Marine Leproust, Chairman, President & Chief Executive Officer
• Patrick Weiss, Chief Operating Officer (LinkedIn Profile)
• James M. Thorburn, Chief Financial Officer
• Siyuan Chen, Chief Technology Officer
• Aaron K. Sato, Chief Scientific Officer

What is Emily Leproust's approval rating as Twist Bioscience's CEO?

44 employees have rated Twist Bioscience CEO Emily Leproust on Glassdoor.com. Emily Leproust has an approval rating of 83% among Twist Bioscience's employees.

Who are some of Twist Bioscience's key competitors?

Some companies that are related to Twist Bioscience include argenx (ARGX), Repligen (RGEN), QIAGEN (QGEN), Novavax (NVAX), Acceleron Pharma (XLRN), Neurocrine Biosciences (NBIX), CRISPR Therapeutics (CRSP), Vir Biotechnology (VIR), Abcam (ABCM), Denali Therapeutics (DNLI), Adagio Therapeutics (ADGI), Exelixis (EXEL), Beam Therapeutics (BEAM), Fate Therapeutics (FATE) and Halozyme Therapeutics (HALO).
View all of TWST's competitors.

What other stocks do shareholders of Twist Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Twist Bioscience investors own include CrowdStrike (CRWD), Pfizer (PFE), DocuSign (DOCU), Intel (INTC), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), JD.com (JD), Tesla (TSLA) and Twilio (TWLO).

When did Twist Bioscience IPO?

(TWST) raised $75 million in an initial public offering on Wednesday, October 31st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Cowen acted as the underwriters for the IPO and Allen & Company and Baird were co-managers.

What is Twist Bioscience's stock symbol?

Twist Bioscience trades on the NASDAQ under the ticker symbol "TWST."

Who are Twist Bioscience's major shareholders?

Twist Bioscience's stock is owned by a number of institutional and retail investors. Top institutional investors include Capital World Investors (8.80%), BlackRock Inc. (8.15%), Sumitomo Mitsui Trust Holdings Inc. (4.35%), Nikko Asset Management Americas Inc. (4.35%), Invesco Ltd. (3.59%) and Allianz Asset Management GmbH (3.51%). Company insiders that own Twist Bioscience stock include Emily M Leproust, Emily M Leproust, James M Thorburn, Jan Johannessen, John P Molloy, Keith Crandell, Mark Daniels, Nicolas Barthelemy, Patrick John Finn, Patrick Weiss, Paula Green, Robert Chess and William Banyai.
View institutional ownership trends for Twist Bioscience.

Which institutional investors are selling Twist Bioscience stock?

TWST stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Capital World Investors, Invesco Ltd., Morgan Stanley, Voloridge Investment Management LLC, Marshall Wace LLP, and Cubist Systematic Strategies LLC. Company insiders that have sold Twist Bioscience company stock in the last year include Emily M Leproust, James M Thorburn, Jan Johannessen, John P Molloy, Keith Crandell, Mark Daniels, Nicolas Barthelemy, Patrick John Finn, Patrick Weiss, Paula Green, Robert Chess, and William Banyai.
View insider buying and selling activity for Twist Bioscience or view top insider-selling stocks.

Which institutional investors are buying Twist Bioscience stock?

TWST stock was acquired by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Massachusetts Financial Services Co. MA, BlackRock Inc., Blue Water Life Science Advisors LLC, Dimensional Fund Advisors LP, Allianz Asset Management GmbH, Geode Capital Management LLC, and Macquarie Group Ltd..
View insider buying and selling activity for Twist Bioscience or or view top insider-buying stocks.

How do I buy shares of Twist Bioscience?

Shares of TWST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Twist Bioscience's stock price today?

One share of TWST stock can currently be purchased for approximately $81.14.

How much money does Twist Bioscience make?

Twist Bioscience has a market capitalization of $4.03 billion and generates $90.10 million in revenue each year. The company earns $-139.93 million in net income (profit) each year or ($2.86) on an earnings per share basis.

How many employees does Twist Bioscience have?

Twist Bioscience employs 525 workers across the globe.

What is Twist Bioscience's official website?

The official website for Twist Bioscience is www.twistbioscience.com.

Where are Twist Bioscience's headquarters?

Twist Bioscience is headquartered at 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080.

How can I contact Twist Bioscience?

Twist Bioscience's mailing address is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (800) 719-0671 or via email at [email protected].